Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AmBisome liposomal formulation of the antifungal drug amphotericin B: Partner Fujisawa USA Inc. began a Phase III trial in 660 patients with fever suspected to

NeXstar Pharmaceuticals Inc. (NXTR),

Read the full 46 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE